More selective approaches may offer a viable alternative, as shown recently by blockade of RSPO3, which inhibited tumor growth of PTPRK-RSPO3 fusion-expressing CRC by promoting differentiation and loss of stem-cell function13. This evidence concerns the gene PTPRK and colorectal carcinoma.